Literature DB >> 30027524

Experiences of patients seeking to participate in variant of uncertain significance reclassification research.

Sukh Makhnoon1, Lauren Thomas Garrett2, Wylie Burke3, Deborah J Bowen3, Brian H Shirts4.   

Abstract

Patients' understanding of a genetic variant of unknown clinical significance (VUS) is likely to influence beliefs about risk implications, consequent medical decisions, and other actions such as involvement in research. We interviewed 26 self-selected participants with a clinically identified VUS before they enrolled into a VUS reclassification study. Semi-structured interviews addressed topics including motivation to get genetic test, experience with the VUS result, affective responses to receiving VUS, and perceived effect of VUS and reclassification on medical care. We found that family and personal history of disease were the most prevalent motivators for getting a genetic test. Participants demonstrated mixed understanding of VUS. Most expressed negative effect on learning of their VUS result and uncertainty about its impact on clinical management. Most expected reclassification efforts to benefit their family members but not themselves. Some expressed distrust of their providers following a VUS result. Participation in the VUS reclassification study appeared to be motivated by four factors for patients with VUS-negative effect about VUS, uncertainty about its impact on clinical management, concern for family members' well-being, and to advance science. Perhaps the direct acknowledgement and appraisal of uncertainty as a means of coping was missing in some pre-test counseling experienced by our participants and thus they were not psychologically prepared for atypical VUS results. The finding of VUS-induced provider distrust suggests a need for careful consideration of appropriate pre- and post-test counseling about VUS.

Entities:  

Keywords:  Affective response; Cancer; Oncology; Reclassification; Uncertainty; Understanding; VUS

Year:  2018        PMID: 30027524      PMCID: PMC6435771          DOI: 10.1007/s12687-018-0375-3

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  12 in total

1.  Exploring relatives' perceptions of participation, ethics, and communication in a patient-driven study for hereditary cancer variant reclassification.

Authors:  Ginger J Tsai; Annie T Chen; Lauren T Garrett; Wylie Burke; Deborah J Bowen; Brian H Shirts
Journal:  J Genet Couns       Date:  2020-01-09       Impact factor: 2.537

2.  Perceptions of genetic variant reclassification in patients with inherited cardiac disease.

Authors:  Eugene K Wong; Kirsten Bartels; Julie Hathaway; Charlotte Burns; Laura Yeates; Christopher Semsarian; Andrew D Krahn; Alice Virani; Jodie Ingles
Journal:  Eur J Hum Genet       Date:  2019-03-21       Impact factor: 4.246

Review 3.  Patients' views on variants of uncertain significance across indications.

Authors:  Kristin Clift; Sarah Macklin; Colin Halverson; Jennifer B McCormick; Abd Moain Abu Dabrh; Stephanie Hines
Journal:  J Community Genet       Date:  2019-08-20

Review 4.  Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review.

Authors:  Danielle Gould; Rachel Walker; Grace Makari-Judson; Memnun Seven
Journal:  J Community Genet       Date:  2022-07-12

5.  Is there a way to reduce the inequity in variant interpretation on the basis of ancestry?

Authors:  Paul S Appelbaum; Wylie Burke; Erik Parens; David A Zeevi; Laura Arbour; Nanibaa' A Garrison; Vence L Bonham; Wendy K Chung
Journal:  Am J Hum Genet       Date:  2022-06-02       Impact factor: 11.043

6.  Balancing uncertainty with patient autonomy in precision medicine.

Authors:  Samantha Pollard; Sophie Sun; Dean A Regier
Journal:  Nat Rev Genet       Date:  2019-05       Impact factor: 53.242

7.  Amyotrophic Lateral Sclerosis Genetic Access Program: Paving the Way for Genetic Characterization of ALS in the Clinic.

Authors:  Jennifer Roggenbuck; Kelly A Rich; Leah Vicini; Marilly Palettas; Joceyln Schroeder; Christina Zaleski; Tara Lincoln; Luke Drury; Jonathan D Glass
Journal:  Neurol Genet       Date:  2021-08-10

8.  Patient perspectives on variant reclassification after cancer susceptibility testing.

Authors:  Colin M E Halverson; Laurie M Connors; Bronson C Wessinger; Ellen W Clayton; Georgia L Wiesner
Journal:  Mol Genet Genomic Med       Date:  2020-04-24       Impact factor: 2.183

9.  Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.

Authors:  Jong Won Lee; Woochang Lee; Hyun-Ki Kim; Eun Jin Lee; Young-Jae Lee; Jisun Kim; Yongsub Kim; Kyunggon Kim; Shin-Wha Lee; Suhwan Chang; Young Joo Lee; Sail Chun; Byung Ho Son; Kyung Hae Jung; Yong-Man Kim; Won-Ki Min; Sei-Hyun Ahn
Journal:  J Hum Genet       Date:  2020-01-06       Impact factor: 3.172

10.  Regarding the Yin and Yang of Precision Cancer- Screening and Treatment: Are We Creating a Neglected Majority?

Authors:  Colleen M McBride; Yue Guan; Jennifer L Hay
Journal:  Int J Environ Res Public Health       Date:  2019-10-29       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.